Codon

JUNE 2, 2025

” By 2003, collaborators had cultivated frog meat grown from cells, preceding the scientific and market interests in cultured meats. The torso was treated with a partial programming gene therapy. A decade passed before, in 2013 , scientist Mark Post would famously create and consume a burger grown from stem cells.

Engineering 67

Engineering Therapies DNA Trials 67

Codon

NOVEMBER 1, 2024

A first draft was published in 2003; it was a patchwork of sequenced DNA from multiple people. Today, a single injection of an FDA-approved gene therapy, called Hemgenix , cures this disease. Department of Energy and National Institutes of Health initiated a 15-year plan to map ‘the sequence of all 3.2

DNA 132

DNA RNA Molecular Biology Laboratories 132

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Peripheral blood NK cells have been used in allogeneic cancer therapies and shown to be safe. developing immune stem cell therapies for treating ovarian and gastric cancer.

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

NOVEMBER 17, 2020

1, 2003, and Dec. Zaira Aversa, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a population-based cohort study involving children born in Olmsted County, Minnesota, between Jan. 31, 2011, to examine the impact of antibiotic exposure in the first two years of life.

Therapies 52

Therapies Doctors Disease Research 52

The Pharma Data

AUGUST 13, 2020

Approximately 460,000 patients in the US have been treated with Xolair since its first approval for allergic asthma back in 2003. If approved, patients will be able to self-administer Xolair once the therapy has been established and closely observed in a healthcare setting. Source link.

FDA 52

FDA Clinical Development Treatment Therapies 52

Drug Target Review

MAY 18, 2023

Results of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia published in the Journal of the American Medical Association in 2003, indicated that the use of hydroxyurea, the only drug approved at the time, reduced mortality as it reduced pain crises and increased foetal haemoglobin.

Disease 80

Disease Clinical Trials Drugs Trials 80

Drug Target Review

SEPTEMBER 11, 2024

morDAC enable single or dual-targeting strategies that deliver a combination therapy in a single therapeutic agent and have significantly enhanced anti-aggregation effects compared to the parental molecules alone. These are still early days in the development of morADC – we are at least a couple years from entering clinical trials.

Small Molecule 52

Small Molecule Disease Therapies Drugs 52

The Pharma Data

OCTOBER 21, 2020

Founded in 2003, Athenex, Inc. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. BUFFALO, N.Y., About Athenex, Inc.

Engineering 40

Engineering Therapies Treatment International 40

Drug Target Review

DECEMBER 14, 2023

The new understanding may result in novel cancer therapies. In 2003, Dr Richard Wood, distinguished Professor at the University of Texas MD Anderson Cancer Center, was a crucial part of the first characterisation of polymerase theta. Polymerase theta TMEJ has been the most elusive DNA repair pathway.

DNA 59

DNA Clinical Trials Treatment Research 59

The Pharma Data

APRIL 14, 2021

After Xolair therapy has been initiated and safely established in a healthcare setting, a healthcare provider may determine whether self-injection with Xolair prefilled syringe by the patient or a caregiver is appropriate. “The with Xolair since its initial approval in 2003. Approximately 460,000 patients have been treated in the U.S.

FDA Approval 52

FDA Approval Clinical Development FDA Treatment 52

The Pharma Data

JUNE 26, 2021

“Currently available therapies only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer’s. director of the FDA’s Center for Drug Evaluation and Research. These changes affect a person’s ability to remember and think.

FDA 40

FDA Drugs Disease Therapies 40

NIH Director's Blog: Drug Discovery

MAY 9, 2019

Similarly, when the complete human genome sequence was revealed for the first time in 2003, commentators (including me) referred to this as the moment where the book of life for humans was revealed. When NIH’s Marshall Nirenberg and his colleagues cracked the genetic code in 1961, it was called the solution to life’s greatest secret.

Engineering 52

Engineering Regulations Science Research 52

Drug Channels

FEBRUARY 23, 2021

Approximately one out of four payers strongly agrees that accumulators could have the potential to discourage appropriate utilization of specialty therapies. Dave Marley has just sold Marley Drug, the independent pharmacy he founded in 2003, to Medicure Pharma. Sometimes, the little guy wins big. Marley Drug generated $1.7

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Independent Pharmacies 52

The Pharma Data

NOVEMBER 9, 2020

Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and they are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. NBTXR3 is injected one time, directly into solid tumors. Abstract ID: 410.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

DECEMBER 15, 2020

NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. What makes this new therapy particularly exciting is the 5-day course of treatment and its good tolerability. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

2003) , and Biogen lnt’l v. The PTO’s not-even-specious-argument, citing what certainly appears to us to be absolutely irrelevant case law, such as Novartis AG v. Ezra Ventures LLC, 909 F.3d 3d 1367 (Fed. 2018) , Arnold Partnership v. Rogan , 246 F. 2d 460 (E.D. Banner Life Sciences LLC, 956 F.3d 3d 1351 (Fed.

FDA Approval 59

FDA Approval FDA Production Therapies 59

The Premier Consulting Blog

JANUARY 17, 2023

The Pediatric Research Equity Act (PREA) was signed into law in 2003 to increase pediatric use information in product labeling and close knowledge gaps regarding the safety, efficacy, and appropriate dosing of drugs to treat children.

Production 52

Production Clinical Trials FDA Disease 52

The Pharma Data

NOVEMBER 5, 2020

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. from 1993 to 1995.

Pharmaceuticals 40

Pharmaceuticals Analytical Chemistry Small Molecule Therapies 40

Drug Target Review

FEBRUARY 14, 2025

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997.

Drugs 52

Drugs Research Immune Response Science 52

Agency IQ

JUNE 7, 2024

Active medical devices fall into these categories: MD 1100 general active medical devices, MD 1200 devices for imaging, MD 1300 monitoring devices, MD 1400 devices for radiation and thermo therapy. Series AIMD 0100 describes all active implantable device types.

Regulations 40

Regulations Compliance Packaging Production 40

Agency IQ

SEPTEMBER 15, 2023

D’Agostino noted the context of Covid-19 and the upcoming flu season, saying, “We have the opportunity to push people to more effective therapies, so there’s a real risk of spreading more disease.” Gottlieb also worked in leadership positions at FDA and CMS from 2003 to 2007. He penned thoughts on LinkedIn following the vote.

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

The Pharma Data

DECEMBER 23, 2020

It is approved in Argentina as the world’s first therapy for severe Chronic Fatigue Syndrome and is the only late-stage drug in the U.S. In addition, many survivors of the first SARS-CoV-1 epidemic in 2003 continued to report classic chronic fatigue-like symptoms after recovering from the acute illness. development pipeline for ME/CFS.

Clinical Trials 52

Clinical Trials Trials Virus Therapies 52

The Pharma Data

OCTOBER 19, 2020

NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.

Clinical Trials 40

Clinical Trials Immune Response Trials Therapies 40

PLOS: DNA Science

OCTOBER 17, 2024

The original approved was in 2003 to treat a type of Gaucher disease. Until today, there were no approved therapies in the US. The new drug is taken with miglustat , which FDA approved for use in NPD3 in 2009. But like many new treatments for a rare disease, the price is high.

Disease 52

Disease FDA Approval Drugs Treatment 52

BMG Labtech

MARCH 8, 2023

In biology , scientific research on cell metabolism focuses on different topics such as understanding the fundamental metabolic processes, metabolic changes and their role in diseases (including cancer cell and tumor metabolism), the development of therapies, the identification of unknown metabolic processes and metabolites, etc.

Molecular Biology 52

Molecular Biology Production Cell Based Assays Disease 52

The Pharma Data

MAY 13, 2021

Nutritional Therapy Practitioner. 2003 ACE Personal Trainer of the Year. Mike Robertson, MS, CSCS, USAW is the co-owner of Indianapolis Fitness and Sports Training and the President of Robertson Training Systems in Indianapolis, Indiana. Thanks for creating this great product, Rick.â??. Jeff Salzenstein. Denver, Colorado. Stephen Holt.

Production 52

Production Treatment Vaccine Therapies 52

New Drug Approvals

JULY 10, 2023

If FDA approved, it will join other previously-approved “-gepant” drugs [ rimegepant ] and [ ubrogepant ] as an additional treatment alternative for patients with migraine, particularly those for whom traditional triptan therapy has proven ineffective. New Haven, CT.

Clinical Trials 40

Clinical Trials Treatment Trials FDA 40

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

APRIL 25, 2021

Editor’s note: In January 2021, nirsevimab received the Promising Innovative Medicine (PIM) Designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and was also granted the Breakthrough Therapy Designation (BTD) by the China Center for Drug Evaluation (CDE) under the National Medical Products Administration.

Virus 40

Virus Trials Disease Hospitals 40

Drug Target Review

OCTOBER 4, 2023

10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects. Dual payload ADCs As effective as therapies have been in treating solid and haematological cancers, tumour heterogeneity and resistance remain major clinical challenges. 1 , 33–43 (2018). Cancer Res.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

NOVEMBER 30, 2023

Then I was approached to co-found AC Immune in 2003. Our investigational active immunisation therapies could potentially delay or perhaps even prevent the onset of clinical dementia symptoms. My family and friends said I was crazy to take this step. COVID-19 has shown the revolutionary impact of vaccines.

Disease 95

Disease Therapies Laboratories Treatment 95

The Pharma Data

JULY 22, 2021

We believe patients, family members and physicians deserve the facts about the therapy and the process by which it was approved so they may make informed decisions. ADUHELM is the first Alzheimer’s treatment approved since 2003. The approval of ADUHELM by the U.S. This cycle of innovation is common in the biopharmaceutical industry.

Disease 52

Disease Research Clinical Trials FDA 52

The Pharma Data

MAY 5, 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).

Therapies 52

Therapies Disease Treatment International 52

The Pharma Data

FEBRUARY 12, 2022

The approval extends the current indication in China as add-on therapy in adults and children aged five years and older with active systemic lupus erythematosus (SLE). 8) despite standard therapy. Benlysta, combined with standard therapy, is indicated in adult patients with active lupus nephritis. About lupus.

Production 52

Production Therapies Trials Disease 52

The Pharma Data

MARCH 26, 2021

The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE. positive anti-dsDNA and low complement) despite standard therapy. positive anti dsDNA and low complement) despite standard therapy. About the BLISS-LN study.

Therapies 52

Therapies Treatment Disease Vaccine 52

Codon

DECEMBER 17, 2023

A first draft of the human genome was completed in 2003. At least six CAR-T cancer therapies have now garnered F.D.A. Laundry may not be as immediately headline-grabbing as new cancer therapies, but it provides a concrete and ingenious solution to a demonstrable need. Mechanisms: Biotechnology shouldn’t be a mystery.

Engineering 52

Engineering Molecular Biology Doctors DNA 52